Menopausal Hormone Treatment for Women with Endometriosis
Women with a history of endometriosis entering menopause should receive combined estrogen-progestin hormone therapy, NOT estrogen-only therapy, regardless of whether they have had a hysterectomy. 1
Critical Principle: Always Add Progestin
The 2026 Canadian endometriosis guidelines explicitly state that estrogen-only menopausal hormone therapy (MHT) carries a higher risk of disease reactivation and must be avoided in patients with known endometriosis, including those who have had a hysterectomy 1. This represents a departure from standard practice where hysterectomized women typically receive estrogen-only therapy.
Why This Matters
- Endometriosis persists or recurs in 2-5% of postmenopausal women, even without hormone therapy 1
- Estrogen-only therapy stimulates residual endometriotic tissue and increases malignancy risk 2, 3
- A 2026 case report documented multiple recurrences over two decades in a woman on unopposed estrogen pellet therapy, despite prior hysterectomy and bilateral oophorectomy 2
Specific Hormone Therapy Recommendations
Preferred regimens for women with endometriosis history:
Combined continuous estrogen-progestin formulations (first-line) 1, 4
- Use any standard combined preparation
- Continue progestin component even after hysterectomy
Tibolone (alternative option) 4, 5
- May reduce recurrence risk compared to estrogen-only therapy
- Limited data but appears safer than unopposed estrogen
Route of administration considerations:
When to Strongly Recommend MHT
Mandatory consideration for MHT in these scenarios:
- Premature or early menopause (before age 45) - should be offered MHT until at least age 50-51 to prevent cardiovascular disease and osteoporosis 1, 7
- Surgical menopause - particularly important given increased cardiovascular and bone health risks 7, 5
- Severe vasomotor symptoms - MHT remains most effective treatment 8, 6
Women with endometriosis often undergo bilateral oophorectomy or repeated ovarian surgeries, placing them at higher risk for early menopause and its complications 7. Additionally, prior GnRH agonist therapy may have already compromised bone density 1.
Monitoring for Recurrence
If endometriosis symptoms recur on MHT:
- Evaluate clinically - respond to symptom recurrence rather than routine imaging 4
- If endometrioma growth occurs - malignancy must be ruled out 1
- Consider imaging - MRI is preferred modality for detecting lesions and assessing malignancy risk 5
- Surgical excision remains gold standard for both diagnosis and treatment of postmenopausal endometriosis 9, 5
Medical Management of Recurrence
If recurrence occurs and MHT must be discontinued:
- Aromatase inhibitors may be considered for postmenopausal endometriosis, as peripheral estrogen production from adipose tissue can drive disease activity 1, 5
- This targets the main source of estrogen in postmenopausal women
Common Pitfalls to Avoid
Critical errors in management:
Prescribing estrogen-only therapy after hysterectomy - the uterus is irrelevant; progestin protects against endometriosis reactivation, not just endometrial hyperplasia 1, 2
Withholding MHT entirely due to endometriosis history - the benefits of MHT in early/premature menopause outweigh recurrence risks when combined formulations are used 7, 5
Using unopposed high-dose estrogen preparations - pellet therapy and other supraphysiologic formulations carry particularly high recurrence risk 2
Failing to counsel about recurrence possibility - women should be informed to report pelvic pain or other symptoms suggestive of reactivation 7
Alternative Options
If combined MHT is contraindicated or declined:
- Non-hormonal therapies for vasomotor symptoms (SSRIs, gabapentin, fezolinetant)
- Bisphosphonates or other agents for bone protection if indicated
- Avoid herbal preparations - efficacy uncertain and some contain estrogenic compounds 4
Strength of Evidence
The recommendation for combined estrogen-progestin therapy is based on:
- Strong guideline consensus from the 2026 Canadian endometriosis guidelines (conditional recommendation, low-quality evidence) 1
- Consistent expert opinion across multiple international societies 4, 5
- Biological plausibility and case reports demonstrating recurrence with estrogen-only therapy 2, 3
While randomized trial data are lacking, the potential consequences of disease reactivation and malignant transformation justify this precautionary approach 3, 5.